🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

I am deeply honored to be named by the Stanford Medicine Alumni Association this year for the “Arthur Kornberg and Paul Berg Lifetime Achievement Award in Biomedical Sciences.” As a Stanford graduate student in the 1980s, I took a remarkable class in plasmid and phage

1/ 🚨 Now in Blood Cancer Journal - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T in myeloma #MMsm. Typically non-bloody Gr3+ diarrhea starting ~3 mo after ide-cel or cilta-cel: 36% cases fatal in our series (n=14). nature.com/articles/s4140…

🎉Finally out and timely for #ASH24 ASH🎉 Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm Blood Cancer Journal nature.com/articles/s4140…

Getting ready for another round soon!!😄 Marc S. Raab #ASH24

The wait is over!! We are thrilled to announce that we have chosen Spatial Proteomics as 2024’s Method of the Year! 🥳 For more on Spatial Proteomics and a road map to this special issue, please see this month’s Editorial or read on in this thread. nature.com/articles/s4159…

The overflow rooms were overflowing! Important contributions from German study groups GMMG and DSMM in NDMM: impressive 100% MRD negativity with Teclistamab based regimens in HD10 presented by Marc S. Raab and significant PFS benefit with Isa-VRd induction reported by Elias K. Mai MD

Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 Thanos Dimopoulos NEJM Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.10… Slides in thread

AQUILA trial for high risk smoldering myeloma published in NEJM today. Thanos Dimopoulos Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR This story below may help those interested in a clinical trialist career. 1/

Wanna do same slide spatial multi-omics? Check out our new approach, IN-DEPTH, compatible with multiple spatial proteomics and transcriptomics platforms to uncover new biological insights for tumor viruses and the TME! Led by YaoYu Yeo Yuzhou Chang Huaying Qin Ma BMBL

#Myeloma Paper of the Day: Long-term follow-up of Phase 3 GMMG ReLApsE trial of second ASCT finds median PFS was 20.5 & 19.3 months in transplant & control arms; median OS 67.1 and 62.7 months: pubmed.ncbi.nlm.nih.gov/39808798/. #mmsm Overall, does not support routine use of salvage ASCT.

Now out in @BloodJournal: Marc-A. Bärtsch et al./#GMMG: After >8 yrs mFU the #GMMG ReLApsE phIII trial shows no significant survival benefit with salvage transplant vs. len/dex in myeloma regardless of time to progression after frontline transplant. tinyurl.com/wzyyzhdb #mmsm

Would be interested to know if folks are still doing salvage at all… for me it’s become a rare circumstance of someone having an exceptionally long remission from first transplant and often if they weren’t even on rev maintenance.

Finally online in Nature Communications Nature Communications today: nature.com/articles/s4146…. Huge thanks to everyone involved in the study! Sizun Jiang Garry P. Nolan Xavier Rovira Clavé Michael Angelo Shalek Lab YaoYu Yeo and others that are not on this platform lol

📣 We are excited to announce the 10th Heidelberg Myeloma Workshop   Join us on April 25–26, 2025, as international & local experts share the latest advancements in multiple myeloma research. #mmsm ✅ CME-certified 🔗 Speaker line-up & registration 👇🏼 myelomaworkshop.de

Heidelberg Myeloma Marc S. Raab Leo Rasche Elias K. Mai MD Brian Walker Kai Rejeski Krönke Lab Jens Hillengass Marc-A. Bärtsch Mirco J. Friedrich Niccolo Bolli a great event

Time to progression after a frontline autologous transplant does not predict benefit from salvage autologous transplant. ow.ly/QCSm50VCOK6 #clinicaltrialsandobservations #lymphoidneoplasia #multiplemyeloma #transplantation

The optimal management of relapsed and/or refractory multiple myeloma in patients who have previously received frontline high-dose chemotherapy and autologous stem cell transplantation remains a subject of ongoing debate. ow.ly/W5iT50VCOEc #clinicaltrialsandobservations

nizar jacques bahlis Bruno Paiva Tom Cupedo Haas Lab Marc-A. Bärtsch Leo Rasche Dana-Farber Leif Bergsagel Mark Bustoros See you all in 2027 for the 11th Heidelberg Myeloma Workshop

Excited to share our work investigating the mutagenic impact of radiotherapy in hematological cancers out today in Blood Cancer Discovery!! 🎉 Another study born from amazing collaborations across Moffitt Cancer Center Heidelberg Myeloma University of Miami Memorial Sloan Kettering Cancer Center MSK Department of Medicine 💪 #lysm #wgs #RT #mmsm

1/ Another exciting year for myeloma #MMsm research! (IMROZ & BENEFIT last year seem like ages ago...) I'll miss #ASCO25 and #EHA2025 on paternity leave, but here are my top 10 #MMsm abstracts spanning CD38, BCMA, GPRC5D, and more... Thanks Mike Thompson, MD, PhD, FASCO as always for compiling!